Evidence map›Paper›PMID 38351680›Full record

ArticleThe Korean journal of internal medicine2024

Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion.

Jaehee Lee, Deok Heon Lee, Ji Eun Park, Yong Hoon Lee, Sun Ha Choi, Hyewon Seo, Seung Soo Yoo, Shin Yup Lee, Seung-Ick Cha, Jae Yong Park and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jaehee LeeDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Deok Heon LeeDepartment of Thoracic and Cardiovascular Surgery, School of Medicine, Kyungpook National University, Daegu, Korea.
Ji Eun ParkDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Yong Hoon LeeDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Sun Ha ChoiDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Hyewon SeoDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Seung Soo YooDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Shin Yup LeeDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Seung-Ick ChaDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Jae Yong ParkDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Chang Ho KimDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Kyungpook National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsEpidermal growth factor receptor (EGFR) mutation is important in determining the treatment strategy for advanced lung cancer patients with malignant pleural effusion (MPE). Contrary to serum carcinoembryonic antigen (S-CEA) levels, the associations between pleural fluid CEA (PF-CEA) levels and EGFR mutation status as well as between PF-CEA levels and treatment efficacy have rarely been investigated in lung adenocarcinoma patients with MPE.

methodsThis retrospective study enrolled lung adenocarcinoma patients with MPE and available PF-CEA levels and EGFR mutation results. The patients were categorized based on PF-CEA levels: < 10 ng/mL, 10-100 ng/mL, 100-500 ng/mL, and ≥ 500 ng/mL. The association between PF-CEA levels and EGFR mutation status as well as their therapeutic impact on overall survival was compared among the four groups.

resultsThis study included 188 patients. PF-CEA level was found to be an independent predictor of EGFR mutation but not S-CEA level. The EGFR mutation rates were higher as the PF-CEA levels increased, regardless of cytology results or sample types. Among EGFR-mutant lung adenocarcinoma patients receiving EGFR-tyrosine kinase inhibitor (TKI) treatment, those with high PF-CEA levels had significantly better survival outcomes than those with low PF-CEA levels.

conclusionHigh PF-CEA levels were associated with high EGFR mutation rate and may lead to a favorable clinical outcome of EGFR-TKI treatment in EGFR-mutant lung adenocarcinoma patients with MPE. These findings highlight the importance of actively investigating EGFR mutation detection in patients with suspected MPE and elevated PF-CEA levels despite negative cytology results.

Indexed as

Adenocarcinoma of LungLung NeoplasmsPleural EffusionPleural Effusion, MalignantCarcinoembryonic AntigenErbB ReceptorsHumansMutationProtein Kinase InhibitorsRetrospective StudiesCarcinoembryonic AntigenErbB ReceptorsProtein Kinase InhibitorsEpidermal growth factor receptorMalignant pleural effusionMutationPleural fluid–carcinoembryonic antigenTyrosine kinase inhibitor

Identifiers

PMID38351680
PMCPMC10918375
OpenAlexW4391820424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.